Rituxan Turns in Good Safety Profile in RA MedPage Today WASHINGTON -- Serious infectious events associated with rituximab (Rituxan) remain consistently low in rheumatoid arthritis (RA) patients for nearly a decade after first treatment, researchers said here. Infusion-related reaction was the most frequent ... |
